Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) announced that the multi-center, randomized, double-blind, placebo-controlled phase III clinical trial (REBUILDING-2) of the safety and efficacy of RAY1225 injection, an innovative polypeptide drug independently developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as “Zhongsheng Ruichuang”), the holding subsidiary of the company, recently obtained top-line analysis data. Preliminary results showed that RAY1225 injection showed positive efficacy and good safety in Chinese adult obesity/overweight participants. The test results were ideal and achieved the intended goals.

RAY1225 injection (Bilpatide Injection, bilpatide injection) is an innovative structural polypeptide drug with global independent intellectual property rights developed by Zhongsheng Ruichuang. It has the dual stimulatory activity of GLP-1 receptors and GIP receptors. Thanks to its excellent pharmacokinetic properties, it has the potential to be injected every two weeks as an ultra-long-lasting drug.

The REBUILDING-2 clinical trial recently completed data cleaning and locking, obtained top-line analysis results, and reached the main end point. RAY1225 injection is significantly superior to placebo in many key secondary efficacy indicators, such as improvements in major efficacy indicators and various cardiovascular and metabolic risk factors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.